2026 Healthline Survey: GLP-1 Expectations vs. Personal Experiences

Common GLP-1 side effects may occur less frequently than expected

Gastrointestinal side effects are often a concern when considering GLP-1 medications. The Healthline Survey, however, suggests that what people expect to experience may not always match what those taking a GLP-1 actually report.

For example, nausea and vomiting were the most expected side effects, with 67% of people considering a GLP-1 anticipating them. By comparison, 34% of those currently or previously taking a GLP-1 actually reported these symptoms.

The rate still represents about 1 in 3 people experiencing these effects, suggesting that nausea and vomiting may be symptoms worth preparing for when starting treatment.

Other well-known GLP-1 side effects showed a similar gap between the expectations of people considering treatment and the experiences of people who have taken a GLP-1:

• Injection site reactions: anticipated by 42% of people considering a GLP-1, but reported by 15% of those currently or previously taking a GLP-1
• Diarrhea: expected by 39%, but reported by 25%
• Dizziness or lightheadedness: expected by 35%, compared with 20% who experienced it
• Rapid heart rate or palpitations: expected by 23%, but reported by 9%

Less-discussed GLP-1 side effects may more closely match real-life reports

For some less-talked-about symptoms, expectations appear to be closer to what people actually experience:

• Constipation: anticipated by 24% of people considering a GLP-1 and reported by 25% of those who had taken one
• Sleep changes (insomnia and vivid dreams): expected by 11% and reported by 13%
• Feeling cold: expected by 10% and reported by 12%

The biggest difference involved sulfur burps or gas. Only 10% of people expected this GLP-1 side effect, but 17% of respondents actually experienced it during their treatment.

Why this matters

Fear of side effects can shape decisions before a treatment even begins. People considering a GLP-1 may assume nausea, vomiting, diarrhea, or injection site reactions are almost inevitable parts of treatment.

Concerns about side effects may keep someone from starting a medication they need, lead them to experience every new sensation as a sign that their body isn’t tolerating it, or cause them to overlook less-talked-about side effects.

The Healthline Survey results cannot predict what any one person will or will not experience on a GLP-1. But they may offer a more realistic starting point to replace a sense of inevitability with a practical plan:

• know what symptoms are possible
• understand which can usually be managed
• clarify what would warrant a medication review

Being aware of both common and less common symptoms can help you begin treatment informed and prepared, while leaving room for your experience to be different from what you may have expected.

Dramatic changes in the face, body, and skin less common than expected

Facial volume loss, often referred to as “Ozempic face,” has become one of the more widely discussed GLP-1-related concerns. The Healthline Survey, however, suggests that expectations of these effects may exceed what people who take GLP-1s experience.

Among respondents planning to take a GLP-1, 44% expected to experience drastic facial changes as a result of treatment. In comparison, 20% of those who had taken a GLP-1 actually experienced this side effect.

A similar gap emerged around changes in skin texture. While 39% of prospective patients expected loose or sagging skin after taking a GLP-1, 18% of those who had taken one reported these changes.

The closer match between expectations and experience was around muscle loss or reduced physical strength, a longer-term side effect of rapid weight loss with GLP-1s.

Of people considering a GLP-1, 23% anticipated losing muscle mass as a result, while 21% of those taking a GLP-1 actually experienced this side effect.

What do you wish you knew before taking GLP-1s?

“The fact that you need to exercise as the weight comes off fast and weakens your muscles.”

— _{Respondent from the 2026 Healthline GLP-1 Survey, currently taking a GLP-1 (3-6 months)}

Read more: A Guide for Deciding If GLP-1s Are Right for You

Why this matters

For someone deciding whether to start, continue, or stop treatment with a GLP-1, it can be difficult to tell which experiences are common and which receive the most attention because they sound drastic or extreme.

Changes in the face or skin, for example, are easy to photograph and share. Celebrity stories about appearance changes after GLP-1 treatment may also attract significant attention, often without much context. Changes in strength may be less visible, but they can affect everyday function and quality of life.

It is important to keep the Healthline Survey’s findings in context. People report what they noticed about themselves; the survey did not measure facial volume, skin texture, or muscle mass. The findings also cannot determine whether GLP-1 medication directly caused any particular change.

Experiences may also vary based on factors like:

• starting body weight
• percentage and pace of weight loss
• dietary habits
• age
• activity levels
• other health factors

These may influence how people experience treatment and how they report those experiences with GLP-1s.

For people taking a GLP-1, paying attention to both function and appearance can provide a fuller picture of how treatment is affecting them. Signs of declining strength may include having more difficulty:

• climbing stairs
• carrying groceries
• exercising
• getting up from a chair

GLP-1 weight loss close to expectations, well-being less predictable

Weight loss was the most widely expected and reported benefit of GLP-1s. Among people considering treatment, 81% expected to lose weight, while 75% of all people who had taken a GLP-1 reported weight loss.

Of those who reported weight loss, time on treatment made a difference. Overall, 71% of respondents who had taken a GLP-1 for 6 months or fewer reported losing weight, compared with 80% of those who’d taken the medication for more than 7 months.

That difference may reflect the fact that GLP-1s are often prescribed as a long-term treatment for obesity or diabetes. The body typically needs time to adjust to the medication before changes become noticeable.

When it came to appetite control, people’s experiences closely matched their expectations. Many reported feeling less hungry or experiencing less “food noise,” a common term for persistent or intrusive thoughts about food.

Of those considering a GLP-1, 63% expected reduced food cravings, while 59% of those currently or formerly taking one reported it. This remained fairly consistent across treatment stages.

In general, many people appeared to expect GLP-1 weight loss to unlock a much broader change in how they felt every day.

Nearly half of the people considering treatment expected weight loss to bring more energy or improved mobility, but only 29% of people who had taken a GLP-1 reported these benefits. In contrast, 29% of people who had taken a GLP-1 reported fatigue as a side effect.

Improved self-confidencewas also reported less often than people expected from a GLP-1.

Fifty percent of people considering treatment anticipated improved confidence or body image, but only 37% of those who had taken a GLP-1 reported experiencing these benefits. The share was higher among people who had taken a GLP-1 for at least 7 months and had lost weight: 44% reported improved confidence or body image.

A similar gap appeared for sleep quality. While 35% of people anticipated better sleep if they took a GLP-1, only 20% of those who took a GLP-1 reported this benefit.

Why this matters

The Healthline Survey cannot tell us whether staying on a GLP-1 longer inevitably leads to greater weight loss or overall benefits. But the results do suggest that the first 3 months on a GLP-1 may not always provide a complete picture when assessing treatment success.

Results during the first few weeks of GLP-1 treatment may look quite different from results closer to the 1-year mark, so treatment progress may need to be viewed within a longer timeline.

The findings also suggest that losing weight with GLP-1s isn’t always accompanied by improvements in well-being.

For this reason, understanding whether new symptoms are related to medication side effects or the consequences of rapid weight loss is essential for preventing and managing them effectively.

It’s also important to recognize when a GLP-1 side effect may be serious or affect quality of life, as this can help identify opportunities to seek professional support, rather than discontinue GLP-1 treatment.

For example, fatigue with GLP-1s is often linked to eating too little, inadequate nutrient intake, dehydration, sleep problems, or other underlying health factors.

Similarly, joint pain or limited mobility may persist even after weight changes if other forms of support aren’t in place. Lifestyle factors, such as activity levels and activity type, may also influence these challenges.

“Feeling better” may also be too broad to use as a GLP-1 treatment goal. More specific goals provide a clearer way to evaluate progress.

Depending on why a GLP-1 medication is prescribed, goals that may be easier to measure include:

• changes in appetite
• A1C levels
• daily blood sugar markers
• body mass index (BMI)
• ability to enjoy or complete certain activities

Tracking dose changes, side effects, and lifestyle modifications in context can provide a more useful view of progress and treatment results.

Treatment length and post-treatment experience are top concerns

Among people currently taking a GLP-1 for weight loss, the Healthline Survey found that 67% expected to stop treatment within 2 years, compared with 35% of those taking the medication for diabetes or blood sugar management. That suggests people may plan GLP-1 treatment differently depending on why they started.

Concerns about side effects, unknown long-term effects, and the cost of GLP-1s were among the reasons some people expected or planned for a shorter treatment timeline.

Fifty-six percent of all people surveyed worried about regaining weight after stopping GLP-1s. That concern rose to 68% among people considering starting treatment.

“I wish I knew how hard it would be to keep the weight off. Originally, I did not know about that until my first break a few years ago, which is why I got back on.“

— _{Respondent from the 2026 Healthline GLP-1 Survey, currently taking a GLP-1 (7-12 months)}

Why this matters

GLP-1 medications affect appetite and fullness. When treatment ends, those effects tend to fade. Hunger may return, and maintaining weight loss and blood sugar levels without any other aid can become difficult for many.

Although the Healthline Survey did not measure how many people actually regained weight after stopping a GLP-1, reported concerns are consistent with findings from clinical research.

In an extension of the STEP 1 trial, participants regained two-thirds of the weight they had lost within 1 year of stopping semaglutide (Wegovy, Ozempic).

In the SURMOUNT-4 trial, people who stopped tirzepatide (Mounjaro, Zepbound) regained weight during the following year, while those who continued treatment lost additional weight.

These results and the Healthline Survey findings suggest that a “stopping plan” may need to begin way before the last dose.

Someone considering discontinuing a GLP-1 could benefit from reviewing the specifics of their medication and working with a healthcare professional to determine:

• what to monitor and track during treatment
• how to manage returning hunger or changes in blood sugar
• what lifestyle habits can sustain weight and blood sugar management long term
• whether another treatment or support may be needed

What the 2026 Healthline Survey adds to the GLP-1 conversation

The Healthline Survey’s most useful contribution may be to provide a reference point between two extremes: the broad averages found in clinical research and the highly individual stories shared by people taking GLP-1s.

Here are the main conclusions:

^{_{This article includes proprietary data from RVOH Consumer Surveys, which we conduct regularly to better understand real-world health challenges. This research provides context alongside external scientific studies, but it may not reflect all individual experiences. For more on how we gather this information, check the RVO Health Consumer Surveys Methodology.}}